Naurex Inc. Announces Initiation of Phase I Trial for Second-Generation Novel Antidepressant Agent NRX-1074
6/4/2013 9:17:45 AM
More...
|
Naurex Inc. Completes $38 Million Series B Financing
12/17/2012 7:41:09 AM
More...
|
Naurex Inc. Release: Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
12/6/2012 9:35:32 AM
More...
|
Naurex Inc.'s Novel Antidepressant GLYX-13 Recognized as One of Windhover Information Inc.'s 2011 Top 10 Neuroscience Projects to Watch
11/7/2011 12:29:19 PM
More...
|
Naurex Inc. Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression
6/22/2011 8:30:46 AM
More...
|
Naurex Inc. Raises $18 Million to Advance Novel Antidepressant
5/11/2011 6:16:04 AM
More...
|
New Preclinical Data Confirm Naurex Inc.'s Novel Antidepressant GLYX-13 Appears Free of the Behavioral Impairment and Abuse Potential Seen With Ketamine
12/7/2010 9:11:54 AM
More...
|
Naurex Inc.: Preclinical Data at Neuroscience 2010 Show Naurex's Novel Antidepressant GLYX-13 Shares Key Efficacy Mechanisms with Ketamine
11/17/2010 6:55:39 AM
More...
|
Naurex Inc.'s Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch
8/31/2010 9:03:11 AM
More...
|
Naurex Inc. Presents Positive Clinical Data on Novel Mechanism Antidepressant Candidate GLYX-13 at NCDEU 50th Anniversary Meeting
6/17/2010 12:01:46 PM
More...
|
|